Form 4: Evolent Health President Awarded Significant Restricted Stock Units

Evolent Health, Inc. President Daniel Joseph McCarthy was granted 44,767 restricted stock units as part of the company's annual compensation cycle, aligning executive incentives with shareholder interests.

Summary

• Daniel Joseph McCarthy, President of Evolent Health, Inc. (EVH), was granted 44,767 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• The grant was made on July 1, 2025, as part of the annual award cycle approved by the Compensation Committee.
• These RSUs will vest over three years: 34% on July 1, 2026, 33% on July 1, 2027, and the remaining 33% on July 1, 2028.
• The award was contingent upon shareholder approval of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, which occurred on June 5, 2025, at the Company's Annual Meeting.
• Following this transaction, Mr. McCarthy's total beneficial ownership of Evolent Health, Inc. securities, including previously reported awards, stands at 433,771 shares.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation grant, which is generally positive as it aligns executive interests with shareholders, but it does not contain information that would significantly alter the company's financial outlook or strategic direction.

Positives

• The grant of restricted stock units to a key executive like the President aligns management's long-term interests with those of the shareholders.
• The vesting schedule encourages executive retention and sustained performance over multiple years.
• Shareholder approval of the incentive plan demonstrates good corporate governance and transparency regarding equity compensation.

Future Outlook

The granted restricted stock units are scheduled to vest in three tranches on July 1, 2026, July 1, 2027, and July 1, 2028, indicating a future alignment of executive compensation with long-term company performance.

Management Comments

• The award was approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle, reflecting the company's ongoing executive compensation strategy.

Industry Context

The grant of restricted stock units is a common practice in the healthcare technology and services industry for executive compensation, designed to attract, retain, and incentivize key leadership by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of restricted stock units with a multi-year vesting schedule is a standard compensation mechanism widely adopted by publicly traded companies across various sectors, including healthcare, to foster long-term executive commitment and align interests with shareholders.
• This type of equity award is comparable to those seen in other growth-oriented healthcare IT companies, where a significant portion of executive compensation is tied to equity performance.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Daniel Joseph McCarthy, the President of Evolent Health, Inc., constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees (Executive): Daniel Joseph McCarthy receives significant equity compensation, incentivizing his continued contribution and performance.

Next Steps

• The restricted stock units will vest in three annual installments, with the first vesting occurring on July 1, 2026.

Key Dates

Keywords

Evolent Health, EVH, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Stock Grant, Form 4, Equity Award, Corporate Governance